The structural elucidation of the norovirus 3C protease bound to a peptide inhibitor provides critical information for the development of targeted antiviral therapies.
Answers are grounded in this paper and cite their sources.
Atomic details of norovirus 3C protease inhibition may guide antiviral design; leaves open clinical translation.
Noroviruses are the major cause of human epidemic nonbacterial gastroenteritis. Viral replication requires a 3C cysteine protease that cleaves a 200 kDa viral polyprotein into its constituent functional proteins. Here we describe the X-ray structure of the Southampton norovirus 3C protease (SV3CP) bound to an active site-directed peptide inhibitor (MAPI) which has been refined at 1.7 Å resolution. The inhibitor, acetyl-Glu-Phe-Gln-Leu-Gln-X, which is based on the most rapidly cleaved recognition sequence in the 200 kDa polyprotein substrate, reacts covalently through its propenyl ethyl ester group (X) with the active site nucleophile, Cys 139. The structure permits, for the first time, the identification of substrate recognition and binding groups in a noroviral 3C protease and thus provides important new information for the development of antiviral prophylactics.
No takes yet. Share an insight, caveat, or question.
Hussey et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: